Mark Ragosa - 23 Jul 2024 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
25 Jul 2024, 16:32:39 UTC
Prior SEC filing
30 Apr 2024
Next SEC filing
04 Sep 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Madelyn Zeylikman, Attorney-in-Fact
Filing notes and source

Key filing fact

Mark Ragosa filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 25 Jul 2024.

Key facts

  • This page summarizes Mark Ragosa's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
  • 3 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 25 Jul 2024, 16:32.

Change

  • Previous filing in this sequence was filed on 30 Apr 2024.
  • Current net transaction value: -$331,955.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
$269,153
Shares
+24,248
Change %
+126%
Price
$11.10
Shares after
43,501
Date
23 Jul 2024
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Sale

Transaction value
-$601,108
Shares
-24,248
Change %
-56%
Price
$24.79
Shares after
19,253
Date
23 Jul 2024
Ownership
Direct
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Options Exercise

Transaction value
$0
Shares
-24,248
Change %
-38%
Price
$0.000000
Shares after
40,412
Date
23 Jul 2024
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
24,248
Exercise price
$11.10
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 3 footnotes

Footnote F1

This transaction was effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 22, 2023.

Footnote F2

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $24.72 and $25.095. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Footnote F3

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .